DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,866,302 | -14.8% | 240,396 | -7.0% | 0.17% | -6.1% |
| Q2 2023 | $62,067,600 | -4.0% | 258,615 | +0.8% | 0.18% | -6.7% |
| Q1 2023 | $64,653,300 | -6.1% | 256,520 | -1.1% | 0.19% | -9.8% |
| Q4 2022 | $68,875,959 | +0.8% | 259,498 | -1.9% | 0.21% | -12.7% |
| Q3 2022 | $68,337,000 | -1.7% | 264,576 | -3.5% | 0.24% | +18.9% |
| Q2 2022 | $69,486,000 | -14.6% | 274,083 | -1.2% | 0.21% | -2.4% |
| Q1 2022 | $81,370,000 | -15.0% | 277,400 | -4.6% | 0.21% | -5.8% |
| Q4 2021 | $95,712,000 | +6.3% | 290,908 | -1.6% | 0.22% | -3.0% |
| Q3 2021 | $90,005,000 | +11.0% | 295,644 | -2.1% | 0.23% | +11.1% |
| Q2 2021 | $81,070,000 | +9.0% | 302,094 | -8.6% | 0.21% | -2.8% |
| Q1 2021 | $74,377,000 | +5.5% | 330,446 | +4.1% | 0.21% | +13.2% |
| Q4 2020 | $70,483,000 | +4.7% | 317,292 | +1.5% | 0.19% | -5.5% |
| Q3 2020 | $67,341,000 | +9.1% | 312,735 | -10.4% | 0.20% | -3.8% |
| Q2 2020 | $61,713,000 | +24.3% | 348,996 | -2.7% | 0.21% | +0.5% |
| Q1 2020 | $49,635,000 | +17.7% | 358,615 | +30.5% | 0.21% | +46.8% |
| Q4 2019 | $42,188,000 | +331.8% | 274,882 | +306.3% | 0.14% | +291.7% |
| Q3 2019 | $9,771,000 | +1873.9% | 67,657 | +1852.0% | 0.04% | +1700.0% |
| Q2 2019 | $495,000 | -3.1% | 3,466 | -10.3% | 0.00% | 0.0% |
| Q1 2019 | $511,000 | -50.6% | 3,866 | -61.4% | 0.00% | -60.0% |
| Q4 2018 | $1,034,000 | +120.5% | 10,025 | +131.8% | 0.01% | +150.0% |
| Q3 2018 | $469,000 | -54.3% | 4,325 | -58.4% | 0.00% | -50.0% |
| Q2 2018 | $1,026,000 | +142.6% | 10,405 | +140.6% | 0.00% | +100.0% |
| Q1 2018 | $423,000 | +5.5% | 4,325 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $401,000 | -3.6% | 4,325 | -10.8% | 0.00% | 0.0% |
| Q3 2017 | $416,000 | -72.3% | 4,848 | -72.4% | 0.00% | -75.0% |
| Q1 2017 | $1,504,000 | -0.2% | 17,591 | -9.1% | 0.01% | 0.0% |
| Q4 2016 | $1,507,000 | -18.7% | 19,356 | -18.1% | 0.01% | -20.0% |
| Q3 2016 | $1,853,000 | +14.1% | 23,637 | +11.4% | 0.01% | +11.1% |
| Q2 2016 | $1,624,000 | -84.4% | 21,214 | -83.9% | 0.01% | -83.0% |
| Q2 2014 | $10,400,000 | +266.7% | 132,101 | +249.3% | 0.05% | +152.4% |
| Q1 2014 | $2,836,000 | +10.9% | 37,819 | +14.1% | 0.02% | 0.0% |
| Q4 2013 | $2,558,000 | – | 33,138 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |